Edition:
India

DexCom Inc (DXCM.OQ)

DXCM.OQ on NASDAQ Stock Exchange Global Select Market

72.47USD
1:30am IST
Change (% chg)

$-0.27 (-0.37%)
Prev Close
$72.74
Open
$72.76
Day's High
$73.40
Day's Low
$72.04
Volume
281,618
Avg. Vol
396,809
52-wk High
$81.81
52-wk Low
$42.63

Chart for

About

Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company's products consist of DexCom G4 PLATINUM and DexCom G5 Mobile. The... (more)

Overall

Beta: 0.22
Market Cap(Mil.): $4,132.42
Shares Outstanding(Mil.): 86.56
Dividend: --
Yield (%): --

Financials

BRIEF-FDA Authorizes Marketing Of New Dexcom G6 CGM Eliminating Need For Fingerstick Blood Testing

* FDA AUTHORIZES MARKETING OF THE NEW DEXCOM G6® CGM ELIMINATING NEED FOR FINGERSTICK BLOOD TESTING FOR PEOPLE WITH DIABETES

28 Mar 2018

BRIEF-U.S. FDA Says Permitted Marketing Of Dexcom G6 Integrated Continuous Glucose Monitoring System

* U.S. FDA SAYS PERMITTED MARKETING OF THE DEXCOM G6 INTEGRATED CONTINUOUS GLUCOSE MONITORING (ICGM) SYSTEM

28 Mar 2018

BRIEF-Dexcom Inc Q4 GAAP Loss Per Share $0.11

* DEXCOM REPORTS RECORD FOURTH QUARTER AND FISCAL YEAR 2017 FINANCIAL RESULTS

28 Feb 2018

BRIEF-DexCom Says Preliminary Q4 Revenue Was $218 Mln

* DEXCOM REPORTS RECORD PRELIMINARY, UNAUDITED REVENUE FOR THE FOURTH QUARTER AND FISCAL YEAR 2017 AND PROVIDES INITIAL 2018 OUTLOOK

09 Jan 2018

BRIEF-Dexcom announces development agreement with Lilly

* Dexcom announces development agreement with Lilly to integrate Dexcom CGM into connected diabetes ecosystem

21 Nov 2017

BRIEF-Dexcom Inc reports Q3 GAAP loss per share $0.02

* Dexcom, inc. Reports record third quarter 2017 financial results

02 Nov 2017

BRIEF-‍Tandem Diabetes Care to provide all t:slim X2 insulin pump features approved in 2018 to users at no cost

* ‍Tandem Diabetes Care to provide all t:slim x2 insulin pump features approved in 2018 to users at no cost, expands existing dexcom welcome offer for animas customers​

25 Oct 2017

Competitors

  Price Chg
Roche Holding Ltd. (ROG.S) CHF215.65 -0.85
Roche Holding Ltd. (RO.S) CHF220.00 -0.20
Johnson & Johnson (JNJ.N) $126.66 -0.89
Abbott Laboratories (ABT.N) $59.19 -0.69
Medtronic PLC (MDT.N) $79.90 -0.10

Earnings vs. Estimates